Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of Non Hodgkins Lymphoma (NHL). Rituximab to be included in CD20 positive patients.